As part of the NHS response to Coronavirus (COVID-19), we have made changes to the services we provide
The study will continue to test the effectiveness of the Novavax COVID-19 vaccine candidate and will be led by the Trust’s highly skilled and experienced Research and Innovation Department who specialise in research and clinical trials.
Liz Glaves, MPFT’s Research Delivery Manager who is managing the study said, “The study team are excited that the crossover research study has begun and we are pleased to have welcomed back so many of the volunteers who took part in the initial Novavax Covid-19 vaccine study.
“My MPFT colleagues and I are proud to be leading the crossover research study locally, again with support from our partners at the National Institute of Health Research, Clinical Research Network (CRN) West Midlands, Keele University and colleagues within Primary Care.”
CRN West Midlands' Acting Clinical Director Professor Matthew Brookes added, “This important vaccine trial is an excellent example of collaborative working with partnership organisations in our Network and we are pleased to continue supporting this next phase. Offering studies like this to our population is important, in order to give a wide and diverse access to participants to allow them to become involved in research studies.”
The vaccine study has sites across the United Kingdom. The West Midlands study based in Staffordshire recruited over 500 suitable local volunteers.
Ruth Lambley-Burke, Head of Research and Innovation at the Trust said; “Clinical research continues to be extremely important in the fight against COVID-19 and we are pleased to continue to play our role in the phase 3 Novavax clinical study in the West Midlands.”